People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| HistoSonics, Inc. | — | Other Health Care | Series D+ | $308.2M | $1.0B | 2024 |
| Biolinq Inc | — | Biotechnology | Series C | $247.4M | $618.5M | 2023 |
| Lenz Therapeutics, Inc. | — | Biotechnology | Series C | $136.2M | $1.2B | 2023 |
CHRIS DIMITROPOULOS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside CHRIS DIMITROPOULOS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 1 | 8 |
| Daniel Bradbury | 1 | 7 |
| Mark - Lester | 1 | 6 |
| Zach Scheiner | 1 | 6 |
| JAMES ADOX | 1 | 5 |
| V. Kadir Kadhiresan | 1 | 5 |
| Linda Tufts | 1 | 5 |
| Jon Freeman | 1 | 5 |
| Gerry Brunk | 1 | 5 |
| Nancy Hong | 1 | 4 |
| Zina Affas Besse | 1 | 4 |
| Stefan Larson | 1 | 4 |
| Kadir Kadhiresan | 1 | 4 |
| Michael Blue | 1 | 4 |
| James McCollum | 1 | 3 |
| Dan Bradbury | 1 | 3 |
| Andrew Von Eschenbach | 1 | 3 |
| Wen Chen | 1 | 3 |
| RICHARD YANG | 1 | 2 |
| Akhil Tripathi | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.